… routine use of molnupiravir for COVID-19 treatment in … -19 who were treated with molnupiravir
[absolute risk reduction (… outpatients with risk factors treated with molnupiravir. Moreover, …

… coronavirus (MERS-CoV) virus replication and pathogenesis. In a SARS-CoV-2 ferret model,
molnupiravir treatment … ability of treatment to reduce and eliminate infectious SARS-CoV-2 …

… the Covid-19 treatment armamentarium. Another advantage of molnupiravir over SARS-CoV-2 …
is the efficacy of molnupiravir against SARS-CoV-2 variants. The mechanism of action of …

… of Molnupiravir and Favipiravir in the SARS-CoV-2 … virus titers in the lungs, the combination
causes a >4.5 log 10 reduction of such titers. When start of the combination treatment was …

… Molnupiravir (MOV) is a broad-spectrum oral antiviral agent approved for the treatment of …
against many RNA viruses such as influenza virus and some alphaviruses agents of epidemic …

… Molnupiravir initially emerged as a possible treatment of … epithelial cell culture against
SARS-CoV-2. Improvement in … infected with SARS-CoV-2 that were administered molnupiravir [6]. …

… of SARS-CoV-2 in type-2 pneumocytes [25]. In addition, molnupiravir therapy completely
blocked SARS-CoV-2 … We believe that early molnupiravir treatment in asymptomatic or mildly …

… drug candidate for the treatment of patients with COVID-19 is molnupiravir (or EIDD-2801), …
the effects of molnupiravir or NHC on the RNA synthesis activity of SARS-CoV-2 RdRp using …

… molnupiravir and nirmatrelvir for treating Omicron-infected patients. We further call the initiation
of clinical studies to evaluate the combination of molnupiravir and nirmatrelvir for treating …

… A combination of molnupiravir with favipiravir and other antivirals is also possible due to
their synergistic effects for the treatment of new variants of SARS-CoV-2. At the time of …